數據顯示今年首三季上市宗數創2000年科網泡沫以來最多
《路透》引述Refinitiv數據顯示,全球新股上市於第三季放緩,但今年首三季累計上市個案仍爲2000年科網泡沫以來最高。
今年第三季新股上市集資946億美元,按季減少26.3%。總計首三季共有2,000多宗上市個案,累計集資4,210億美元,爲紀錄新高。當中包括486宗特殊目的收購公司(SPAC)上市個案,集資額1,277億美元。
季內較矚目上市包括網上券商羅賓漢(HOOD.US)在紐約的21億美元上市案,與及南韓軟件公司Krafton在南韓交易所的37億美元上市案。今年以來最大宗上市案爲快手(01024.HK)的54億美元上市案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.